RIPK1 and neoplasm: RIPK1 was significantly upregulated in tumour cells of immune checkpoint blockade (ICB)-resistant murine models, where it drives TME immunosuppression by recruiting suppressive myeloid cells and impairing cytotoxic lymphocyte infiltration.21